| scholarly article | Q13442814 |
| P356 | DOI | 10.1164/AJRCCM.153.2.8564110 |
| P698 | PubMed publication ID | 8564110 |
| P2093 | author name string | Rogers RM | |
| Calhoun WJ | |||
| Donahoe M | |||
| de Godoy I | |||
| Mancino J | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| TNF | Q18032037 | ||
| P304 | page(s) | 633-637 | |
| P577 | publication date | 1996-02-01 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients | |
| P478 | volume | 153 |
| Q47707074 | Airway and systemic inflammation and decline in lung function in patients with COPD. |
| Q50539530 | An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. |
| Q44484408 | Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease |
| Q36909567 | Aspects on pathophysiological mechanisms in COPD. |
| Q35536791 | Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis |
| Q92479876 | Association between tumor necrosis factor-α and chronic obstructive pulmonary disease: a systematic review and meta-analysis |
| Q82022906 | Biomarkers of systemic inflammation in stable and exacerbation phases of COPD |
| Q47665346 | Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study |
| Q37139528 | COPD as a systemic disease |
| Q51557746 | Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. |
| Q35208742 | Chronic obstructive pulmonary disease * 12: New treatments for COPD |
| Q28384754 | Chronic obstructive pulmonary disease patients have greater systemic responsiveness to ex vivo stimulation with swine dust extract and its components versus healthy volunteers |
| Q35009945 | Chronic obstructive pulmonary disease. 5: systemic effects of COPD |
| Q37016623 | Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease |
| Q36443665 | Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities |
| Q35925432 | Chronic obstructive pulmonary disease: epidemiology, pathogenesis, disease course, and prognosis |
| Q42869917 | Circulating TNF alpha receptor levels identify older adults who fail to regain weight after acute weight loss |
| Q38180799 | Cytokine networking of innate immunity cells: a potential target of therapy. |
| Q35561670 | Cytokine-directed therapies for the treatment of chronic airway diseases |
| Q44775847 | Determinants of BMI in patients with COPD. |
| Q36203159 | Differences in local versus systemic TNFalpha production in COPD: inhibitory effect of hyaluronan on LPS induced blood cell TNFalpha release |
| Q41502195 | Early and long-term functional outcomes following lung volume reduction surgery |
| Q41903378 | Effects of TNF-alpha and leptin on weight loss in patients with stable chronic obstructive pulmonary disease |
| Q37636173 | Effects of inhaled therapy on biomarkers of systemic inflammation in stable chronic obstructive pulmonary disease |
| Q59326211 | Elevated Levels of IL-18 in Plasma and Skeletal Muscle in Chronic Obstructive Pulmonary Disease |
| Q84137156 | Elevated TNFalpha production in whole blood in patients with severe COPD: the potential link to disease severity |
| Q91605371 | Elevated serum Activin A in chronic obstructive pulmonary disease with skeletal muscle wasting |
| Q44765657 | Energetic cost of breathing, body composition, and pulmonary function in horses with recurrent airway obstruction |
| Q46724175 | Enhanced exercise-induced plasma cytokine response and oxidative stress in COPD patients depend on blood oxygenation |
| Q37441610 | Evaluation of BODE index and its relationship with systemic inflammation mediated by proinflammatory biomarkers in patients with COPD. |
| Q38110749 | Factors limiting exercise tolerance in chronic lung diseases |
| Q47785823 | First study of infliximab treatment in patients with chronic obstructive pulmonary disease |
| Q36309975 | Genetics and the Dutch Hypothesis. |
| Q51765768 | Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. |
| Q36478484 | Increased production of hydrogen peroxide by peripheral blood monocytes associated with smoking exposure intensity in smokers. |
| Q26830867 | Inflammation and Nutritional Science for Programs/Policies and Interpretation of Research Evidence (INSPIRE). |
| Q33880491 | Inflammatory cytokine response to exercise in alpha-1-antitrypsin deficient COPD patients 'on' or 'off' augmentation therapy. |
| Q36148605 | Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects |
| Q36376453 | Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting? |
| Q44542244 | Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease |
| Q35829778 | Leptin in anorexia and cachexia syndrome |
| Q36362185 | Malnutrition and ageing. |
| Q92263277 | Malnutrition impairs mitochondrial function and leukocyte activation |
| Q35879714 | Management of severe COPD. |
| Q36490588 | Mechanisms of physical activity limitation in chronic lung diseases |
| Q34442689 | Metabolic phenotype and adipose tissue inflammation in patients with chronic obstructive pulmonary disease |
| Q38071124 | Monoclonal antibodies for asthma and chronic obstructive pulmonary disease |
| Q35536202 | Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. |
| Q42218886 | NF-κB activation is required for the transition of pulmonary inflammation to muscle atrophy |
| Q34742138 | New treatments for COPD. |
| Q88771482 | Nutrition in chronic obstructive pulmonary disease: A review |
| Q34149572 | Nutritional abnormalities and supplementation in chronic obstructive pulmonary disease |
| Q36281779 | Nutritional management of the patient with chronic obstructive pulmonary disease |
| Q35690112 | Nutritional modulation as part of the integrated management of chronic obstructive pulmonary disease |
| Q24202330 | Nutritional supplementation for stable chronic obstructive pulmonary disease |
| Q24244188 | Nutritional supplementation for stable chronic obstructive pulmonary disease |
| Q33978274 | Nutritional supplementation in stable chronic obstructive pulmonary disease |
| Q41611564 | Nutritional support in advanced lung disease. The pulmonary cachexia syndrome |
| Q37742694 | Oxidative stress in COPD and its measurement through exhaled breath condensate. |
| Q82918703 | Pathology of chronic obstructive pulmonary disease |
| Q34149532 | Peripheral muscle dysfunction in chronic obstructive pulmonary disease |
| Q36201980 | Physical activity and modulation of systemic low-level inflammation |
| Q46859866 | Physical activity counteracts increased whole-body protein breakdown in chronic obstructive pulmonary disease patients |
| Q37196808 | Plasma inflammatory biomarkers response to aerobic versus resisted exercise training for chronic obstructive pulmonary disease patients |
| Q37162926 | Plasma leptin and insulin-like growth factor I levels during acute exacerbations of chronic obstructive pulmonary disease |
| Q33683010 | Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score |
| Q35885857 | Prospects for new drugs for chronic obstructive pulmonary disease |
| Q28294825 | Protein-energy malnutrition in dialysis patients |
| Q34774443 | Pulmonary cachexia |
| Q46057464 | Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients |
| Q36293943 | Relationship between BODE index, quality of life and inflammatory cytokines in COPD patients |
| Q35771480 | Reversal of chronic obstructive pulmonary disease-associated weight loss : are there pharmacological treatment options? |
| Q37413293 | Role of T-lymphocytes and pro-inflammatory mediators in the pathogenesis of chronic obstructive pulmonary disease. |
| Q37664782 | Sarcopenia correlates with systemic inflammation in COPD. |
| Q35963109 | Serum Vitamin A and Inflammatory Markers in Individuals with and without Chronic Obstructive Pulmonary Disease |
| Q46019769 | Short-term influences of lung volume reduction surgery on the diaphragm in emphysematous hamsters. |
| Q24792076 | Skeletal muscle dysfunction in chronic obstructive pulmonary disease |
| Q39857892 | Stress and inflammation: a biobehavioral approach for nursing research |
| Q42764765 | Systemic inflammation and progression of COPD. |
| Q36686862 | Systemic inflammation in COPD: is genetic susceptibility a key factor? |
| Q35779864 | Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease |
| Q36726350 | Systemic manifestations in chronic obstructive pulmonary disease. |
| Q34045375 | TNFA-863 polymorphism is associated with a reduced risk of chronic obstructive pulmonary disease: a replication study |
| Q89685940 | Targeting IL-17A/glucocorticoid synergy to CSF3 expression in neutrophilic airway diseases |
| Q37168309 | The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year |
| Q44550733 | The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease |
| Q33829486 | Tissue wasting in patients with chronic obstructive pulmonary disease |
| Q39725353 | To what extent and why are COPD and Willis-Ekbom disease associated? |
| Q53667372 | Tumor necrosis factor-alpha and malnutrition-induced inhibition of diaphragm fiber growth in young rats. |
| Q24806646 | Tumor necrosis factor-alpha and muscle wasting: a cellular perspective |
| Q51568269 | Tumor necrosis factor-α driven inflammation in alpha-1 antitrypsin deficiency: a new model of pathogenesis and treatment. |
| Q22305600 | Undernutrition in patients with COPD and its treatment |
| Q35028812 | Update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease |
| Q79840217 | [Comorbidities of COPD] |
| Q77784930 | [Function of respiratory muscles in malnutrition and in the critically ill patient] |
| Q82707696 | [Prognostic markers of COPD. Role of comorbidity] |
| Q73829239 | [The role of peripheral muscles on exercise tolerance in patients with COPD] |
Search more.